TrialJournal of neurology2026

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Xavier Montalban et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.